bladder cancer

downfall

Biotech

EnGene cancer sales forecast cut after new data widen gap to J&J

Leerink analysts slashed their forecast for enGene’s bladder cancer candidate after phase 2 data dented their belief that the biotech can match J&J.

Nick Paul Taylor May 8, 2026 9:08am

cancer target detection radiopharma radio

Protara sees 66% bladder cancer response rate at 6 months

Feb 24, 2026 6:50am

Deal terminate tear up end deal scrap

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

Nov 6, 2025 10:00am

Tecentriq

Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm

White arrow on a road pointing to the rising sun

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

Apr 28, 2025 7:25am

cancer target detection radiopharma radio

Acrivon stops testing Lilly castoff for ovarian, bladder cancer

Mar 26, 2025 7:05am